open access
Immature platelet fraction in cardiovascular diagnostics and antiplatelet therapy monitoring
Affiliations- First Department of Cardiology, Medical University of Warsaw, Poland
- Department of Clinical Chemistry and Laboratory Diagnostics, Medical University of Warsaw, Poland
- Department of Laboratory Diagnostics, Medical University of Warsaw, Poland
- Department Department of Cardiology, Hypertension and Internal Medicine, Medical University of Warsaw, Poland
- Department of Immunology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland
- Department of Pathophysiology and Immunology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
open access
Abstract
Immature platelet fraction (IPF), circulating platelets still containing RNA, can be easily calculated by automated flow cytometry, this makes them an accessible biomarker. Higher IPF concentrations were reported in patients with thrombocytopenia, patients who were smokers, and also those who were diabetics. Several studies have reported their diagnostic and prognostic importance in patients presenting with acute coronary syndromes, especially ST-segment myocardial infarction, where increased IPF level is an independent predictor of cardiovascular death. In addition, higher IPF were reported in patients with inadequate response to either clopidogrel or prasugrel, suggesting their potential role in antiplatelet therapy monitoring. Their prognostic significance was also observed in both coronary artery disease and postcardiac surgery status, where their higher levels correlated with the risk of major adverse cardiac events. The present review aims to present the current evidence on diagnostic, prognostic and potentially therapeutic roles of IPF in cardiovascular medicine.
Abstract
Immature platelet fraction (IPF), circulating platelets still containing RNA, can be easily calculated by automated flow cytometry, this makes them an accessible biomarker. Higher IPF concentrations were reported in patients with thrombocytopenia, patients who were smokers, and also those who were diabetics. Several studies have reported their diagnostic and prognostic importance in patients presenting with acute coronary syndromes, especially ST-segment myocardial infarction, where increased IPF level is an independent predictor of cardiovascular death. In addition, higher IPF were reported in patients with inadequate response to either clopidogrel or prasugrel, suggesting their potential role in antiplatelet therapy monitoring. Their prognostic significance was also observed in both coronary artery disease and postcardiac surgery status, where their higher levels correlated with the risk of major adverse cardiac events. The present review aims to present the current evidence on diagnostic, prognostic and potentially therapeutic roles of IPF in cardiovascular medicine.
Keywords
immature platelet fraction, antiplatelet therapy monitoring, acute coronary syndromes
About this articleTitle
Immature platelet fraction in cardiovascular diagnostics and antiplatelet therapy monitoring
Journal
Issue
Article type
Review Article
Published online
2023-03-10
Page views
160
Article views/downloads
114
DOI
10.5603/CJ.a2023.0019
Pubmed
Keywords
immature platelet fraction
antiplatelet therapy monitoring
acute coronary syndromes
Authors
Karolina Gumiężna
Piotr Baruś
Grażyna Sygitowicz
Agnieszka Wiśniewska
Dorota Ochijewicz
Karolina Pasierb
Dominika Klimczak-Tomaniak
Ewa Kuca-Warnawin
Janusz Kochman
Marcin Grabowski
Grzegorz Opolski
Mariusz Tomaniak
Krzysztof J. Filipiak
References (43)- Thon JN, Italiano JE. Does size matter in platelet production? Blood. 2012; 120(8): 1552–1561.
- Denis MM, Tolley ND, Bunting M, et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell. 2005; 122(3): 379–391.
- McBane RD, Gonzalez C, Hodge DO, et al. Propensity for young reticulated platelet recruitment into arterial thrombi. J Thromb Thrombolysis. 2014; 37(2): 148–154.
- Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med. 2006; 354(19): 2034–2045.
- Italiano JE, Shivdasani RA. Megakaryocytes and beyond: the birth of platelets. J Thromb Haemost. 2003; 1(6): 1174–1182.
- Ault KA, Rinder HM, Mitchell J, et al. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol. 1992; 98(6): 637–646.
- Thompson CB, Eaton KA, Princiotta SM, et al. Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function. Br J Haematol. 1982; 50(3): 509–519.
- Martin JF, Trowbridge EA, Salmon G, et al. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res. 1983; 32(5): 443–460.
- Brown AS, Martin JF. The megakaryocyte platelet system and vascular disease. Eur J Clin Invest. 1994; 24 (Suppl 1): 9–15.
- Deutsch VR, Tomer A. Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside. Br J Haematol. 2013; 161(6): 778–793.
- Martin JF, Kristensen SD, Mathur A, et al. The causal role of megakaryocyte–platelet hyperactivity in acute coronary syndromes. Nat Rev Cardiol. 2012; 9(11): 658–670.
- Joergensen MK, Bathum L. Reference intervals for mean platelet volume and immature platelet fraction determined on a sysmex XE5000 hematology analyzer. Scand J Clin Lab Invest. 2016; 76(2): 172–176.
- Verdoia M, Nardin M, Rolla R, et al. Immature platelet fraction and the extent of coronary artery disease: A single centre study. Atherosclerosis. 2017; 260: 110–115.
- Buttarello M, Mezzapelle G, Freguglia F, et al. Reticulated platelets and immature platelet fraction: Clinical applications and method limitations. Int J Lab Hematol. 2020; 42(4): 363–370.
- Jung H, Jeon HK, Kim HJ, et al. Immature platelet fraction: establishment of a reference interval and diagnostic measure for thrombocytopenia. Korean J Lab Med. 2010; 30(5): 451–459.
- Cannavo I, Ferrero-Vacher C, Sudaka I, et al. [Assessment of an immature platelet fraction (IFP%) in the diagnosis of thrombocytopenia]. Ann Biol Clin (Paris). 2010; 68(4): 415–420.
- Moraes D, Munhoz TP, Pinheiro da Costa BE, et al. Immature platelet fraction in hypertensive pregnancy. Platelets. 2016; 27(4): 333–337.
- Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost. 2009; 101(1): 151–156.
- Cesari F, Marcucci R, Gori AM, et al. Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI-Florence 2 Study. Thromb Haemost. 2013; 109(5): 846–853.
- Ritchie JL, Harker LA. Platelet and fibrinogen survival in coronary atherosclerosis. Response to medical and surgical therapy. Am J Cardiol. 1977; 39(4): 595–598.
- Freynhofer MK, Bruno V, Brozovic I, et al. Is increased platelet turnover responsible for low responsiveness to different thienopyridienes? A case report of recurrent stent thromboses. Thromb Haemost. 2011; 106(1): 182–184.
- Grove EL, Hvas AM, Mortensen SB, et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost. 2011; 9(1): 185–191.
- Guthikonda S, Alviar CL, Vaduganathan M, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol. 2008; 52(9): 743–749.
- Larsen SB, Grove EL, Hvas AM, et al. Platelet turnover in stable coronary artery disease - influence of thrombopoietin and low-grade inflammation. PLoS One. 2014; 9(1): e85566.
- Pedersen OB, Hvas AM, Grove EL, et al. Association of whole blood microRNA expression with platelet function and turnover in patients with coronary artery disease. Thromb Res. 2022; 211: 98–105.
- Jiang P, Song Y, Xu JJ, et al. Two-year prognostic value of mean platelet volume in patients with diabetes and stable coronary artery disease undergoing elective percutaneous coronary intervention. Cardiol J. 2019; 26(2): 138–146.
- Huczek Z, Filipiak KJ, Kochman J, et al. Baseline platelet size is increased in patients with acute coronary syndromes developing early stent thrombosis and predicts future residual platelet reactivity. A case-control study. Thromb Res. 2010; 125(5): 406–412.
- Ibrahim H, Schutt RC, Hannawi B, et al. Association of immature platelets with adverse cardiovascular outcomes. J Am Coll Cardiol. 2014; 64(20): 2122–2129.
- Cesari F, Marcucci R, Caporale R, et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost. 2008; 99(5): 930–935.
- Funck-Jensen KL, Dalsgaard J, Grove EL, et al. Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction. Platelets. 2013; 24(7): 528–537.
- Yahud E, Schilo T, Nevzorov R, et al. Immature platelet fraction over time and clinical outcomes in patients with acute myocardial infarction. Int J Lab Hematol. 2021; 43(5): 966–972.
- Hallén J. Troponin for the estimation of infarct size: what have we learned? Cardiology. 2012; 121(3): 204–212.
- Chia S, Senatore F, Raffel OC, et al. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2008; 1(4): 415–423.
- Bernlochner I, Goedel A, Plischke C, et al. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. Eur Heart J. 2015; 36(45): 3202–3210.
- Fabbri A, Marcucci R, Gori AM, et al. A time course study of high on treatment platelet reactivity in acute coronary syndrome male patients on dual antiplatelet therapy. Thromb Res. 2015; 136(3): 613–619.
- Jäger B, Vargas KG, Haller PM, et al. Immature cell fractions after cessation of chronic P2Y-inhibition in patients with coronary artery diseases. Platelets. 2021; 32(6): 815–820.
- Mavrakanas TA, Chatzizisis YS, Gariani K, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371(23): 2155–2166.
- Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016; 37(14): 1133–1142.
- van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009; 53(16): 1399–1409.
- Stratz C, Bömicke T, Younas I, et al. Comparison of immature platelet count to Established predictors of platelet reactivity during thienopyridine therapy. J Am Coll Cardiol. 2016; 68(3): 286–293.
- Ibrahim H, Nadipalli S, DeLao T, et al. Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness. J Thromb Thrombolysis. 2012; 33(2): 137–142.
- Würtz M, Grove EL, Wulff LN, et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv. 2010; 3(8): 828–835.
- Anetsberger A, Blobner M, Haller B, et al. Immature platelets as a novel biomarker for adverse cardiovascular events in patients after non-cardiac surgery. Thromb Haemost. 2017; 117(10): 1887–1895.
